

---

## Lifecare Q2 2024 - High activity – initial positive signs from longevity trials

Redeye updates its view on Lifecare following the Q2 report and recent company developments, including confirmed sensor longevity of nine weeks in dogs, a strategic cooperation, and a new patent filing, among other things.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

[Lifecare Q2 2024 - High activity – initial positive signs from longevity trials](#)